TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20170881
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g vitamin C infusion (16.6 mg/min, over 1 h before percutaneous coronary intervention)
Study: 20170881
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g vitamin C infusion
Study: 19011435
Drug: Bupropion added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion added to nicotine replacement therapy (NRT) and cognitive behavioral therapy (CBT)
Study: 19011435
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to nicotine replacement therapy (NRT) and cognitive behavioral therapy (CBT)
Study: 15708261
Drug: Cisplatin (C)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (C) - 40 mg/m² weekly for 6 doses concurrent with 50 Gy external beam radiotherapy
Study: 15708261
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus Gemcitabine (GC) - Gemcitabine 125 mg/m² plus Cisplatin 40 mg/m² weekly for 6 doses concurrent with 50 Gy external beam radiotherapy
Study: 28526233
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human KGF (palifermin 60 μg/kg)
Study: 23610448
Drug: Sunitinib (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (oral antiangiogenic tyrosine kinase inhibitor)
Study: 23610448
Drug: Pazopanib (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib (oral antiangiogenic tyrosine kinase inhibitor)
Study: 23610448
Drug: DC101 (antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: DC101 (antibody targeting the VEGF pathway)
Study: 17964811
Drug: Agent with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agent with open eyes
Study: 17964811
Drug: Agent with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agent with sunglasses
Study: 17964811
Drug: Agent with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agent with closed eyes
Study: 17964811
Drug: Agent with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agent with occluders
Study: 16537725
Drug: Fondaparinux 2.5
Normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux 2.5 mg once daily for up to 8 days
Study: 12750950
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium phosphate (NaP) in 2 doses (45 ml + 90 ml) plus domperidone
Study: 12750950
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium phosphate (NaP) in one 90‐ml dose
Study: 12750950
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium phosphate (NaP) in 2 doses (90 ml + 45 ml)
Study: 12750950
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium phosphate (NaP) in 2 doses (45 ml + 90 ml) plus cisapride
Study: 10977009
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g American ginseng (AG)
Study: 10977009
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g (placebo)
Study: 27342494
Drug: Lenalidomide +
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide + chemotherapy (LC)
Study: 27342494
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + placebo (CP)
Study: 22201336
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose etizolam for 2 weeks
Study: 17142005
Drug: Intravenous propacetamol
Normalized name: 1,2,3-propanetriol, 2-(4-aminobenzoate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propacetamol (P) 2 g every 6 hours
Study: 17142005
Drug: Subcutaneous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous morphine (M) 0.05 mg/kg every 4 hours
Study: 12142304
Drug: Relaxation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation and flexibility (control treatment)
Study: 10215768
Drug: ABL 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABL 0.1% in white soft paraffin applied twice daily for 2 weeks
Study: 10215768
Drug: 1.0 microg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 microg/mL ABL
Study: 10215768
Drug: 3.0 microg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 microg/mL ABL
Study: 10215768
Drug: 30 microg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 microg/mL ABL
Study: 10215768
Drug: 1.0 microg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 microg/mL ABL for 8 hours
Study: 10215768
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of ABL 0.01% or 0.1%
Study: 468096
Drug: Gastropulgit Tabs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastropulgit Tabs (2 tablets)
Study: 468096
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (640 mg)
Study: 26796709
Drug: Combined low‐level
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined low‐level laser therapy (LLLT) with passive stretching exercises
Study: 22120829
Drug: ghrelin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ghrelin infusion 1 ng/kg/min
Study: 22120829
Drug: ghrelin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ghrelin infusion
Study: 17382029
Drug: Dual VEGF/EGFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual VEGF/EGFR inhibition (e.g., erlotinib and bevacizumab, or vandetanib)
Study: 2668787
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) 400 and 600 mg per day
Study: 19390123
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (blood glucose set at 80-110 mg/dL)
Study: 19390123
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin therapy (blood glucose maintained at 180-200 mg/dL)
Study: 12008861
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (impulse magnetic-field therapy)
Study: 10493666
Drug: Prolactin (PRL)
Normalized name: prolactin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolactin (PRL) treatment of RA synovial cells
Study: 10493666
Drug: Inhibitors of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibitors of PRL release (e.g., bromocriptine)
Study: 8740792
Drug: Metoclopramide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide plus dexamethasone plus lorazepam (M + D + L)
Study: 1909241
Drug: Nimodipine 30
Normalized name: nimodipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 30 mg tds
Study: 1909241
Drug: Nimodipine 60
Normalized name: nimodipine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 60 mg tds
Study: 1909241
Drug: Nimodipine 90
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine 90 mg tds
Study: 6309637
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg t.i.d.)
Study: 30235049
Drug: TRT using
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRT using 1%‐transdermal T‐gel (50 mg/day)
Study: 18937999
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied once weekly for 24 weeks
Study: 17456819
Drug: Ranolazine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine (1000 mg twice daily, initiated intravenously)
Study: 9737817
Drug: Diltiazem (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (60 mg four times daily for 21 doses)
Study: 9737817
Drug: Diltiazem and
Normalized name: Diltiazem and enalapril only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem and Hydrochlorothiazide (combination)
Study: 9737817
Drug: Hydrochlorothiazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (25 mg twice daily for 11 doses)
Study: 9737817
Drug: Hydrochlorothiazide and
Normalized name: hydrochlorothiazide and potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide and Diltiazem (combination)
Study: 2729379
Drug: Regular coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular coffee (454 +/- 4 mg caffeine)
Study: 2729379
Drug: Decaffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated coffee (12 +/- 0.4 mg caffeine)
Study: 28490712
Drug: Tofacitinib (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib (1 to 30 mg)
Study: 28490712
Drug: Tofacitinib (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib (1 to 100 mg or 5 mg twice daily)
Study: 23673101
Drug: Etoricoxib (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib (120 mg/d)
Study: 23673101
Drug: Indometacin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indometacin (75 mg twice daily)
Study: 19832873
Drug: Second injection
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second injection of glue
Study: 19832873
Drug: Seton treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seton treatment after glue failure
Study: 19716727
Drug: Cavit‐G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cavit‐G
Study: 17477109
Drug: Blocking the
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blocking the mineralocorticoid receptor with anti-aldosterone agents
Study: 11159256
Drug: Carbamazepine (CMZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CMZ) 600 mg/d
Study: 11159256
Drug: Sustained-release morphine
Normalized name: morphine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release morphine 90 mg/d
Study: 2516615
Drug: Sorbiphos (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbiphos (2 g)
Study: 2516615
Drug: Alu-Cap (950
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alu-Cap (950 mg)
Study: 787738
Drug: Mersyndol (analgesic/antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mersyndol (analgesic/antihistamine combination containing paracetamol, codeine phosphate, doxylamine succinate, and caffeine)
Study: 787738
Drug: Mersyndol (analgesic/antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mersyndol (analgesic/antihistamine combination)
Study: 31803945
Drug: SBIRT +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SBIRT + Alcohol Treatment
Study: 31711088
Drug: Implants placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implants placed in surgically bone-grafted sites
Study: 31711088
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of adjacent implants
Study: 28246207
Drug: FOLFIRI/simtuzumab 700
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI/simtuzumab 700 mg
Study: 28246207
Drug: FOLFIRI/simtuzumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI/simtuzumab 200 mg
Study: 19856686
Drug: Fluid replacement
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid replacement therapy
Study: 17053946
Drug: Extracorporeal shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shockwave treatment after open reduction and internal fixation
Study: 17053946
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (open reduction and internal fixation without shockwave treatment)
Study: 17053946
Drug: Extracorporeal shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shockwave treatment
Study: 10916098
Drug: HCTZ (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ (50 mg) + KHCO3 (60 mmol daily)
Study: 10916098
Drug: HCTZ (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ (50 mg) + KCl (60 mmol daily)
Study: 10916098
Drug: KHCO3 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: KHCO3 (60 mmol daily) alone
Study: 9238885
Drug: Oral-B 20
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral-B 20 toothbrush
Study: 30759696
Drug: Moderately hypofractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately hypofractionated radiation therapy (240-340 cGy per fraction)
Study: 30759696
Drug: Ultrahypofractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrahypofractionated radiation therapy (500 cGy or more per fraction)
Study: 30759696
Drug: Ultrahypofractionated external
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrahypofractionated external beam radiation therapy
Study: 30759696
Drug: Image guided
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Image guided radiation therapy
Study: 15170704
Drug: Heparin only
Normalized name: Heparin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin only (Control)
Study: 9638493
Drug: Electromyography and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electromyography and rectal sensitivity studies
Study: 8088394
Drug: Allopurinol 200
Normalized name: allopurinol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 200 mg orally at 24 h and 2 h preoperatively and again at 24 h postoperatively
Study: 2683005
Drug: Alpha human
Normalized name: alpha 1-proteinase inhibitor, human Injection [Glassia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha human leukocyte interferon (IFN) ointment
Study: 21678716
Drug: six-week treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: six-week treatment regimen for type 1 diabetes
Study: 19284948
Drug: Changjishu soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changjishu soft elastic capsule (4 capsules once daily, 3 times a day)
Study: 16702330
Drug: Micronutrient-fortified seasoning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient-fortified seasoning powder (zinc 5 mg, iron 5 mg, vitamin A 270 microg, iodine 50 microg) served with school lunch 5 days/week for 31 weeks
Study: 9093172
Drug: Standard preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preparation of bisacodyl
Study: 25499943
Drug: Mipomersen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mipomersen therapy
Study: 23600790
Drug: Antacid (Milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid (Milk of Magnesia)
Study: 10910606
Drug: HBV-NF vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV-NF vaccine
Study: 7722114
Drug: Carvedilol (3.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (3.125 mg twice a day, titrated to 6.25 to 25 mg twice a day for < 75 kg or 50 mg twice a day for > 75 kg)
Study: 2047947
Drug: Salbutamol 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol 1,000 micrograms by inhalation
Study: 2047947
Drug: Salbutamol 200
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol 200 micrograms by inhalation
Study: 22707179
Drug: Dignity therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dignity therapy (palliative care psychotherapy)
Study: 22078241
Drug: mDOT (directly
Approvals — FDA: no, EMA: no, PMDA: no
Description: mDOT (directly observed daily ribavirin plus provider-administered weekly IFN)
Study: 22078241
Drug: TAU (self-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU (self-administered ribavirin plus provider-administered weekly IFN)
Study: 19735340
Drug: Routine information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine information preparation
Study: 15157731
Drug: Earlier treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Earlier treatment of peripheral retina ablation
Study: 6175933
Drug: Primary chemotherapy
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary chemotherapy (pc)
Study: 6175933
Drug: Secondary chemotherapy
Normalized name: Secondary potassium phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary chemotherapy (sc)
Study: 30859909
Drug: Concurrent Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Control Group
Study: 30227301
Drug: Glutathione 30
Normalized name: ASCORBIC ACID 250 mg in 7 g / .ALPHA.-TOCOPHEROL 20 mg in 7 g / THIAMINE 1 mg in 7 g / MARINE COLLAGEN, SOLUBLE 500 mg in 7 g / PEARL (HYRIOPSIS CUMINGII) 500 mg in 7 g / GLUTATHIONE 300 mg in 7 g / PHLEBODIUM AUREUM LEAF 120 mg in 7 g / PHLEBODIUM AUREUM ROOT 120 mg in 7 g / HYALURONIC ACID 50 mg in 7 g / LYCOPENE 1.15 mg in 7 g / ALOE VERA LEAF 50 mg in 7 g / OPHIOCORDYCEPS SINENSIS 100 mg in 7 g / SOYBEAN 100 mg in 7 g / RICE BRAN 100 mg in 7 g / MARITIME PINE 60 mg in 7 g / HONEY 100 mg in 7 g ORAL POWDER [JBA Collagen-A]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutathione 30 mg L-1
Study: 30227301
Drug: Glutathione 50
Normalized name: glutathione 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutathione 50 mg L-1
Study: 30227301
Drug: Glutathione 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutathione 40 mg L-1
Study: 30227301
Drug: Glutathione 0
Normalized name: glutathione 0.184 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutathione 0 mg L-1 (control)
Study: 26946727
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (0.3 g twice a day), Methotrexate (10 mg once a week), Folic acid (5 mg once a week)
Study: 21795756
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate supplementation (target venous bicarbonate 29 mmol/L)
Study: 21795756
Drug: Previous sodium
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous sodium bicarbonate treatment (target 24 mmol/L)
Study: 19955221
Drug: Joint lavage
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Joint lavage combined with IA steroid injection
Study: 10445610
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate 2 mg x day(-1)
Study: 476023
Drug: Clotrimazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole (100 mg/day for 6 days)
Study: 476023
Drug: Miconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miconazole (100 mg/day for 14 days)
Study: 476023
Drug: Miconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miconazole (100 mg twice daily for 7 days)
Study: 31987323
Drug: 160 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg/kg VE
Study: 31987323
Drug: 320 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 mg/kg VE
Study: 31987323
Drug: 640 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 640 mg/kg VE
Study: 24062180
Drug: Saroglitazar (ZYH1)
Normalized name: Saroglitazar
DrugBank: Saroglitazar (DB13115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saroglitazar (ZYH1) at doses of 0.125, 0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, and 128 mg
Study: 24062180
Drug: Saroglitazar (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saroglitazar (1 mg)
Study: 24062180
Drug: Saroglitazar (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saroglitazar (up to 128 mg)
Study: 19124098
Drug: Prophylactic cement
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic cement injection into non-fractured vertebra adjacent to fractured vertebra
Study: 19124098
Drug: Non-prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-prophylactic treatment (no cement injection)
Study: 11694667
Drug: Atomoxetine 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine 1.8 mg/kg/day
Study: 11694667
Drug: Atomoxetine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine 0.5 mg/kg/day
Study: 11694667
Drug: Atomoxetine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (all doses)
Study: 8981385
Drug: Haloperidol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (2 mg p.o.)
Study: 8981385
Drug: Haloperidol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (2 mg p.o.) + Scopolamine (0.5 mg i.v.)
Study: 8981385
Drug: Metergoline (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metergoline (4 mg p.o.) + Scopolamine (0.5 mg i.v.)
Study: 8518376
Drug: Computer-assisted continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted continuous infusion (CACI)
Study: 8518376
Drug: Manual controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual controlled infusion (MCI)
Study: 2881575
Drug: Topical dimethindene
Normalized name: dimethindene
DrugBank: Dimetindene (DB08801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dimethindene maleate
Study: 31236568
Drug: COBRA-Slim (MTX,
Approvals — FDA: no, EMA: no, PMDA: no
Description: COBRA-Slim (MTX, prednisone step-down from 30 mg)
Study: 31236568
Drug: COBRA-Classic (MTX,
Approvals — FDA: no, EMA: no, PMDA: no
Description: COBRA-Classic (MTX, sulfasalazine, prednisone step-down from 60 mg)
Study: 31236568
Drug: COBRA-Avant-Garde (MTX,
Approvals — FDA: no, EMA: no, PMDA: no
Description: COBRA-Avant-Garde (MTX, leflunomide, prednisone step-down from 30 mg)
Study: 27834686
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg) and folic acid (0.8 mg)